December 26, 2025 A newly released clinical review is drawing attention within medical and regulatory communities by consolidating available evidence on the side-effect profile of a widely prescribed ...

Background Despite anticoagulation, patients with atrial fibrillation (AF) experience persistent elevated cardiovascular risk ...

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 ...

Health IT’s Legacy and the Road to Responsible AI by Dr. S. Yin Ho is an indispensable book about the current state of health information technology and how responsible AI could reshape our U.S.

A parliamentary panel urged India to create a single, independent Ayush drug regulator. It called for unified standards, better ADR reporting, and a digital CTMS to ensure safety and global trust.

Background The growing population of patients with adult congenital heart disease (ACHD) present complex lifelong care needs ...

Coherus Oncology, Inc. is rated a Buy driven by a promising clinical pipeline and undervaluation. Learn more about CHRS stock ...

Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and ...

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.

Congenital heart disease (CHD) management has evolved substantially over recent decades, with transcatheter and hybrid interventions now providing minimally ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety artefacts, evidence repeatability and lifecycle controls. CITY OF LONDON, GB / ACCESS ...